This advert is not available!
In our group, we aim to develop cutting-edge imaging and therapy platform technologies for patients with cancer or cardiovascular diseases. In this project, our primary focus lies with the development of novel molecular imaging and radionuclide therapy strategies for patients with brain cancer. We are offering a unique opportunity to conduct high-quality (pre)clinical research at a world-renowned institute, where you will exploit your scientific creativity, learn new skills, collaborate with national and international leaders in the field and, ultimately, contribute to the improved healthcare of patients with cancer. Our research is highly multidisciplinary, combining recent developments from radiology, oncology, chemistry and molecular biology into innovative nuclear medicine designs, and is carried out at the state-of-the-art research facilities of the Karolinska Institute and MedTechLabs.
Applications are invited from experienced, highly motivated, ambitious radiochemists with a strong chemical background and a positive, can-do attitude. You will synthesise novel radioligands for molecular imaging and radionuclide therapy and participate in their validation in in vitro and in vivo models. A major part of the role includes the organic synthesis of non-radioactive reference compounds for each radioligand.
Qualified to be employed as a postdoctor is one who has obtained a doctorate or has equivalent scientific competence. It is considered as an advantage if you have completed your doctoral degree within the last three years, if there are special reasons, your degree may have been completed earlier. Applicants who have not completed a doctorate at the end of the application period may also apply, provided that all requirements for a completed degree are met before the (intended) date of employment. This must be substantiated by the applicant's main supervisor, director or equivalent.
The ideal candidate will hold a PhD (or an equivalent research competence) in radiochemistry, radiopharmacy or organic chemistry and will have demonstrated expertise in radiopharmaceutical drug design, synthesis and analysis. The candidate should be a strong team player with good collaborative skills. You will have a broad experience in standard (radio) chemical analytical techniques, including but not limited to: NMR, MS, IR, UV-vis, radio-TLC, radio-HPLC. The position requires a candidate with excellent communication skills in English who is motivated to work independently within the team.
Karolinska Institutet is one of the world's leading medical universities. Our vision is to pursue the development of knowledge about life and to promote better health for all. At Karolinska Institutet, we conduct innovative medical research and provide the largest range of biomedical education in Sweden. Karolinska Institutet is a state university, which entitles employees to several benefits such as extended holiday and a generous occupational pension. Employees also have free access to our modern gym and receive reimbursements for medical care.
Location: BioClinicum, Solna
Read more about the research group you will be part of here and here.
Read more about the division of Neuro here.
An employment application must contain the following documents in English or Swedish:
A complete resumé, including date of the thesis defence, title of the thesis, previous academic positions, academic title, current position, academic distinctions, and committee work A complete list of publications A summary of current work (no more than one page)
Welcome to apply at the latest 2022-02-14.
The application is to be submitted through the Varbi recruitment system.
Type of employment | Temporary position |
---|---|
Contract type | Full time |
First day of employment | According to agreement |
Salary | Monthly salary |
Number of positions | 1 |
Full-time equivalent | 100% |
City | Stockholm |
County | Stockholms län |
Country | Sweden |
Reference number | STÖD 2-158/2022 |
Contact |
|
Union representative |
|
Published | 17.Jan.2022 |
Last application date | 14.Feb.2022 11:59 PM CET |